NCT03909594 is a Phase 4 clinical trial of Bupivacaine in Pain, Musculoskeletal, sponsored by Antonios Likourezos.

Who is sponsoring NCT03909594?

NCT03909594 is sponsored by Antonios Likourezos.

What drugs are being tested in NCT03909594?

Interventions in NCT03909594: Bupivacaine, Ketamine.

What condition does NCT03909594 study?

NCT03909594 studies Pain, Musculoskeletal.

Is NCT03909594 still recruiting?

NCT03909594 is currently withdrawn. Last updated 11 October 2021.

Last reviewed 2021-10-11 · How we verify

NCT03909594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone

Withdrawn Phase 4 Last updated 11 October 2021

What this trial tests

Phase 4 trial testing Bupivacaine in Pain, Musculoskeletal. Withdrawn.

Timeline

1 January 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Antonios Likourezos
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	1 January 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across United States

Drugs / interventions tested

Bupivacaine (BUPIVACAINE) — full drug profile →
Ketamine (ketamine) — full drug profile →

Conditions studied

Pain, Musculoskeletal — all drugs for Pain, Musculoskeletal →

Sponsor

Antonios Likourezos — full company profile →

Who can join

Adults 18 to 120, any sex, with Pain, Musculoskeletal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project is meant to evaluate the effect of a combination of medications (Bupivacaine + Ketamine) used in an ultra-sound guided nerve block for patients presenting to the Emergency Department (ED) with hip and/or femur fractures. The goal is to see whether the combination of these two medications will result in greater and longer-lasting pain relief, longer-lasting motor and sensory block and overall less need for opioid rescue analgesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bupivacaine

Trials testing the same drug.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07430085 — Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA · Phase 4 · not yet recruiting
NCT07146685 — Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study · Phase 4 · not yet recruiting

Other recruiting trials for Pain, Musculoskeletal

Currently open trials in the same condition.

NCT06514716 — Intra-articular Corticosteroid Injection in GAE for Knee Knee Osteoarthritis · NA · recruiting

Other Antonios Likourezos trials

Trials by the same sponsor.

NCT06685107 — Virtual Reality and Standard Care vs. Standard Care Alone for Acute MSK Pain in Geriatric ED Patients · NA · recruiting
NCT06473597 — A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache · Phase 4 · recruiting
NCT06364540 — Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED · Phase 4 · recruiting
NCT05227937 — Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study · recruiting
NCT05143489 — The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast: · Phase 4 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03909594 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antonios Likourezos
Last refreshed: 11 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03909594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing